Trial Profile
Oral ONC201 in Recurrent Glioblastoma, H3 K27M-mutant Glioma, and Diffuse Midline Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Glioblastoma; Glioma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Chimerix; Oncoceutics
- 11 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.
- 08 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Dec 2022.